Bloomlife combines connected devices with data analytics to increase access to care, provide personalized feedback to moms, and help doctors earlier predict and manage pregnancy complications. At the center of our solution is a prenatal wearable that tracks critical health parameters of maternal and fetal health. Through our connected care platform we are aggregating first of its kind longitudinal data for digital biomarker discovery to improve risk stratification.  

Bloomlife is a clinical stage women’s health company developing remote prenatal care solutions for the 20% of high risk pregnancies that drive 60% of the $110B annual US healthcare spend. We combine connected devices with data analytics to increase access to care, provide personalized feedback to moms, and help doctors earlier predict and manage pregnancy complications. At the center of our solution is a prenatal wearable that tracks critical health parameters of maternal and fetal health. By addressing modifiable risk factors, detecting abnormalities, and predicting adverse events Bloomlife aims to ensure every family gets a healthy start.

Bloomlife has been recognized for its revolutionary vision and potential to impact lives globally, most recently receiving innovation awards and grants from Johnson & Johnson, Fast Company World Changing Ideas, Maternal and Child Health Bureau, National Science Foundation, and the European Commission Horizon 2020 Initiative.

Biofourmis Care is a holistic, customizable, end-to-end solution that delivers virtual care to patients with acute, post-acute, and chronic medical conditions in the comfort of their own homes. Medical-grade wearables allow for continuous, real-time monitoring and patient-specific notifications enable caregivers to deliver exceptional care to patients anywhere. Our 24/7 virtual clinical care team, staffed by health navigators, nurses, and physicians can monitor and manage patients with acute or chronic medical conditions. Biofourmis Care is powered by the FDA-cleared Biovitals Analytics Engine and Biovitals Index which utilizes artificial intelligence and machine learning to interpret and analyze physiological signals, delivering personalized patient insight. Additional Biofourmis Care features and services include:

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Current antepartum fetal monitoring requires weekly trips to the clinic which is time consuming and inconvenient. For women in underserved communities difficulty accessing care can lead to poor adherence to screening guidelines.

By shifting antepartum fetal monitoring to the home, Bloomlife saves patients time and money, increases adherence to screening guidelines, and frees up valuable clinical resources.

Unlike the competition, Bloomlife does not require messy gels making the product experience more convenient for patients.

Biofourmis Care is a remote patient management solution that can be deployed and scaled across health systems as an enabler or as a provider of care. 

One platform - The Biofourmis platform can support patients across the care continuum, from acute and post-acute conditions to complex chronic diseases.

End-to-End Solution - From patient onboarding, training, delivery logistics, clinical monitoring, billing, and technical support, Biofourmis Care offers every component needed to delivers remote patient care.

FDA-Cleared Analytics Engine - Machine learning model that creates a personalized baseline for individual patients based on continuous physiological signals and uses multiparametric data to derive clinical insights. Shown to significantly reduce false positive notifications in both acute and post-acute care settings.